0.64
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Thiogenesis Therapeutics
Its shares trade on TSX Venture under the ticker TTI.V. It has been listed since 16 July 2019.
Thiogenesis Therapeutics Corp. engages in developing novel drug formulations that act as precursors for rare diseases. The company is headquartered in Toronto, Ontario. The company went IPO on 2019-07-16. The firm is engaged in developing thiol-active therapeutic compounds, which are prodrugs used to treat unmet pediatric medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. The company is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the important obstacles facing thiol-based drugs, their short half-life, strong gastrointestinal (GI) side-effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for mitochondrial disease, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 16 Jul 2019
- Website
- thiogenesis.com ↗
Leadership
Pay as last reported
- Dr. Christopher StarrIndependent Chairman of the BoardC$32,393
- Dr. Patrice RiouxChief Executive Officer, Director, since 2022C$261,683
- Mr. Brook RigginsChief Financial Officer, Secretary, Director, since 2018C$221,778
- Mr. W. Hogan MullallyIndependent DirectorC$32,213
- Ms. Kim TsuchimotoIndependent DirectorC$32,393
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Thiogenesis Therapeutics Corp develops thiol-active therapeutic compounds for rare diseases in Toronto, Canada.
- TTI-0102 is a disulfide prodrug metabolized into cysteamine for treating cystinosis.
- The company focuses on pediatric medical needs with applications in mitochondrial disease and Rett syndrome.
Weaknesses
- The company's lead compound TTI-0102 faces short half-life challenges in thiol-based drugs.
- Thiogenesis Therapeutics Corp has limited market presence in the Canadian pharmaceutical sector.
- The firm's IPO on 16 July 2019 shows early-stage development in drug formulations.
Opportunities
- Thiogenesis Therapeutics Corp can expand TTI-0102 applications to pediatric non-alcoholic steatohepatitis (NASH).
- The company targets unmet medical needs in lysosomal storage diseases like cystinosis.
- Thiogenesis Therapeutics Corp aims to address gastrointestinal side-effects in thiol-based drug treatments.
Threats
- Thiogenesis Therapeutics Corp faces competition from established pharmaceutical firms in rare disease treatments.
- The company must overcome short half-life issues in thiol-based drug formulations.
- Regulatory hurdles may delay TTI-0102 approval for mitochondrial disease applications.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.